Trials / Completed
CompletedNCT00240630
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 646 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sumatriptan succinate/naproxen sodium | Combination Tablet of Treximet |
| DRUG | placebo | placebo to match |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-10-18
- Last updated
- 2015-04-16
Locations
50 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00240630. Inclusion in this directory is not an endorsement.